Although pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy, incremental progress has been realized over the past decade with new chemotherapeutic regimens, advanced surgical techniques, and an improved understanding of genetics. Although most patients are not candidates for surgical resection because of metastatic disease, many centers are focused on offering curative treatment for patients with borderline resectable (BR) or locally advanced (LA) tumors. These patients are treated with chemotherapy and radiation up front followed by surgical resection, and surgery often includes the resection and reconstruction of major blood vessels. In a prospective observational study, Maggino et al1 report the utility of primary chemotherapy for BR and LA PDAC along with the rates of receipt and completion of therapy, conversion to operation, and survival.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Massoumi RL, Hines OJ. Neoadjuvant Therapy of Pancreatic Ductal Adenocarcinoma With Vascular Involvement Shows Promise. JAMA Surg. 2019;154(10):942. doi:https://doi.org/10.1001/jamasurg.2019.2278
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: